Which drug maker spent the most on lobbying this summer? The answer will surprise you

If you guessed Pfizer, Eli Lilly, Amgen — or even any of the megacorporations that make up PhRMA — you’d be wrong. It was Horizon Therapeutics, which markets 11 rare disease drugs here in the U.S. The company spent a whopping $3.49 million on lobbying over the last four months. That’s more than $2 million dollars more than any other pharmaceutical company spent this quarter. Horizon even spent more than the trade association it belongs to, the Biotechnology Innovation Organization.